Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510363 | 1.00 | AAK1 (0.45) | AAK1POLBLMNASCN9ACYP3A4 | |
| SCHEMBL2511238 | 0.88 | POLB (0.43) | POLBLMNAKMT2AMAPK1MEN1 | |
| SCHEMBL2509661 | 0.85 | AAK1 (0.45) | AAK1SCN9AKMT2AATMMEN1 | |
| SCHEMBL2509662 | 0.85 | AAK1 (0.45) | AAK1SCN9AKMT2AATMMEN1 | |
| SCHEMBL2506697 | 0.83 | CTSS (0.44) | AAK1POLBLMNASCN9ACYP3A4 | |
| SCHEMBL2506699 | 0.83 | CTSS (0.44) | AAK1POLBLMNASCN9ACYP3A4 | |
| SCHEMBL2510362 | 0.80 | POLB (0.43) | AAK1POLBLMNASCN9ACYP3A4 | |
| SCHEMBL2507744 | 0.80 | POLB (0.49) | AAK1POLBLMNASCN9AMAPK1 | |
| SCHEMBL2507743 | 0.80 | POLB (0.49) | AAK1POLBLMNASCN9AMAPK1 | |
| SCHEMBL15597950 | 0.79 | POLB (0.48) | AAK1POLBLMNASCN9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | AAK1 836/4885POLB 1278/4885LMNA 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.